Colfax Corporation (CFX)
| Market Cap | 4.59B |
| Revenue (ttm) | 3.13B |
| Net Income (ttm) | -7.45M |
| Shares Out | 118.39M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | 20.28 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $38.73 |
| Previous Close | $39.75 |
| Change ($) | -1.02 |
| Change (%) | -2.57% |
| Day's Open | 39.18 |
| Day's Range | 37.91 - 39.39 |
| Day's Volume | 985,250 |
| 52-Week Range | 14.64 - 40.59 |
After reaching record highs last week, the major indices sold off Monday and have since failed to stage a significant rally. For now, stocks look overstretched, and inflation could be right ar...
The industrial sector is gearing up for growth in 2021. ParkerHannifin (PH), Fortune Brands (FBHS), Reliance Steel (RS), Rexnord (RXN) and Colfax (CFX) are performing well and are set to grow.
Let's see if Colfax (CFX) stock is a good choice for value-oriented investors right now from multiple angles.
Colfax's (CFX) acquisition of LiteCure will create strong growth opportunities for DJO in the physical therapy and rehabilitation market.
Colfax's (CFX) product launches, exposure in multiple markets and gains from buyouts to prove beneficial. However, the pandemic-led challenges and lower selling days remain concerning for Q4.
Colfax's (CFX) Q3 earnings reflect the impacts of poor product demand due to the pandemic, forex woes and a fall in margin. For Q4, it predicts a sequential rise in sales and earnings.
Colfax Corporation (CFX) CEO Matt Trerotola on Q3 2020 Results - Earnings Call Transcript
Colfax (CFX) delivered earnings and revenue surprises of 2.50% and 6.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ANNAPOLIS JUNCTION, MD, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced its financial results for the third quarter...
Colfax (CFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Annapolis Junction, MD, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it will issue a press release providing...
Colfax (CFX) to benefit from growth opportunities in the Fabrication Technology and Medical Technology segments. Also, business in multiple end markets and cost-reduction actions are other tai...
Colfax's (CFX) focus on innovation and product launches along with cost-saving measures might aid performances in the quarters ahead. Adversities caused by the pandemic and high debts are conc...
It appears that investors are starting to take their chips off the table after an incredible run off the coronavirus-led market lows in March. For investors who anticipate that this wave of se...
Colfax (CFX) reported earnings 30 days ago. What's next for the stock?
Colfax's Rate Of Recovery Will Demonstrate The Strength Of Newly Transformed Portfolio
Colfax's (CFX) CEO Matt Trerotola on Q2 2020 Results - Earnings Call Transcript
Colfax's (CFX) Q2 results reflect the adverse impacts of the pandemic on product demand and forex woes. It predicts generating sequentially higher profits and positive cash flow in Q3.
Colfax (CFX) delivered earnings and revenue surprises of 50.00% and 2.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
• Achieved objectives to address COVID-19 impacts, including generating positive cash flow
Colfax (CFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Colfax (CFX), with 41% growth in shares in the past three months, benefits from the overall revival in the broader market, buyout impacts, solid product offerings and cost-saving measures.
Colfax (CFX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Annapolis Junction, MD, July 14, 2020 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it will issue a press release provid...
Colfax (CFX) reported earnings 30 days ago. What's next for the stock?
Colfax (CFX), with a 23% decline in shares so far in 2020, faces the adverse impacts of the pandemic. High debts and forex woes are other concerns.
Colfax Corporation (CFX) CEO Matthew Trerotola on Q1 2020 Results - Earnings Call Transcript
Colfax's (CFX) Q1 results reflect the adverse impacts of the pandemic and contributions from the DJO Global buyout. It withdraws projections for 2020, while expects demand to be the lowest in ...
Colfax (CFX) delivered earnings and revenue surprises of 2.70% and 3.05%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Colfax (CFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Colfax (CFX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
ANNAPOLIS JUNCTION, MD , April 27, 2020 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that due to public health considerations...
Colfax (CFX) is likely to benefit from its focus on strengthening segmental businesses, productivity actions and acquisitions. However, rising cost of sales and high debt remain concerns.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...
Colfax (CFX) reported earnings 30 days ago. What's next for the stock?
Is Colfax (CFX) a great pick from the value investor's perspective right now? Read on to know more.
Colfax (CFX) is likely to benefit from its focus on strengthening segmental businesses and productivity actions, and gains from acquired assets. Cost of sales witnesses a rise.
Colfax Corporation (CFX) CEO Matt Trerotola on Q4 2019 Results - Earnings Call Transcript
Colfax's (CFX) fourth-quarter 2019 results benefit from growth in existing businesses and acquired assets despite forex woes.
Colfax (CFX) delivered earnings and revenue surprises of 8.93% and 0.70%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Colfax (CFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Colfax (CFX) is likely to gain from acquired assets, healthy medical technology business and emerging market exposure. High costs, forex woes and huge debts are concerns.
Colfax (CFX) benefits from acquisitions, productivity actions and product developments. However, escalating costs and a highly leveraged balance sheet are headwinds.
Annapolis Junction, MD, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading global manufacturer of medical technology and fabrication technology products and services...
Colfax (CFX) is likely to continue benefiting from acquisitions, productivity actions and product developments. However, a highly leveraged balance sheet remains a concern.
Colfax's (CFX) third-quarter 2019 results benefit from improved sales performance, with buyouts playing a significant role.
Colfax Corporation (CFX) CEO Matt Trerotola on Q3 2019 Results - Earnings Call Transcript
Colfax (CFX) delivered earnings and revenue surprises of 8.70% and -0.10%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Annapolis Junction, MD, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax”) (NYSE: CFX), today announced that it will be presenting at Baird’s 2019 Global Industrial Conference i...
Colfax (CFX) is likely to gain from opportunities in fabrication technology and orthopedic solutions businesses, buyouts, and emerging market exposure. High costs, huge debts and forex woes ar...
About CFX
Colfax Corporation operates as a diversified technology company worldwide. The company operates through two segments, Medical Technology and Fabrication Technology. The Medical Technology segment offers orthopedic solutions, including orthopedic devices and braces, reconstructive and surgical implants, footwear, bone growth stimulators, and software and services spanning the full continuum of patient care, as well as injury prevention, rehabilitation, pain management, and physical therapy under the Aircast, Chattanooga, CMF, Compex, DonJoy, Pro... [Read more...]
| Industry Specialty Industrial Machinery | IPO Date May 8, 2008 |
| CEO Matthew Trerotola | Employees 15,000 |
| Stock Exchange NYSE | Ticker Symbol CFX |
Analyst Forecasts
According to 18 analysts, the average rating for CFX stock is "Buy." The 12-month stock price forecast is 43.00, which is an increase of 11.03% from the latest price.